Tag: CCS
Stakeholders push two-channel option for CGMs
November 27, 2024Theresa Flaherty, Managing Editor
WASHINGTON – Users of continuous glucose monitors have reported difficulties obtaining equipment and supplies when their insurers eliminate coverage under DME, adding more evidence that there needs to be a two-channel option, stakeholders say.
As CMS has expanded coverage of CGMs and supplies, some payers have begun making it a pharmacy-only benefit, limiting brand choices and narrowing networks.
“One patient wrote that they attempted to obtain sensors from three different...
CCS: ‘There’s something about that DME interaction’
September 27, 2024Theresa Flaherty, Managing Editor
DALLAS – People with diabetes fall off their therapy all the time for a variety of reasons, but DME providers are best equipped to catch them when they do, according to the results of a new study conducted by CCS.
DME patients reinitiated their use of continuous glucose monitors 22% of the time compared to 10% of pharmacy patients, the study found.
“I didn’t expect the difference to be that big,” said Dr. Arti Masturzo, chief medical officer at CCS. “People...
In brief: CGM outcomes, Vent360+ launch, O&P WOY, AdaptHealth refi
September 18, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMID).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs. pharmacy...
Study: Using medical benefit can result in positive outcomes
September 17, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs....
CCS sees AI tool as next step in diabetes care evolution
June 21, 2024Theresa Flaherty, Managing Editor
DALLAS – The volume of data being collected from diabetes patients presents an opportunity to use artificial intelligence to better understand which patients are at risk for non-adherence to therapy, says Richard Mackey, chief technology officer at CCS, which recently launched PropheSee, an AI-powered predictive model for CGM users.
“We want to deliver insights that help them anticipate whatever needs they might have (and identify) situations where some additional support or...
In brief: CCS launches PropheSee, Vertess’ Smith recognized
June 12, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for health care organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk...
CCS Launches AI-powered model
June 11, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification,...
Promotions: Encore Health, CCS
April 25, 2024HME News Staff
LIVINGSTONE, Tenn. – Encore Healthcare has promoted Carrie Proffitt, RRT, to senior vice president of operations. Over the last few years, her role has evolved from clinical operations to overall operations of Encore’s software and service business lines. In her previous role as vice president of clinical operations, Proffitt demonstrated exceptional leadership, dedication and a deep commitment to Encore's mission, the company says.
Dallas-based CCS has named Scott Streator...
In brief: Medtrade’s attendance, CCS’s CVS Health hire
March 29, 2024HME News Staff
DALLAS – Medtrade officials say attendance at the industry’s annual trade show increased 25% this year compared to last year. “This year’s Medtrade attracted more than 2,300 qualified attendees,” said Kerry Tyler, associate show director. The show drew attendees from every state except Rhode Island and from 35 countries, officials say. As part of the New Product Awards sponsored by HomeCare Media at Medtrade, attendees selected Jover Walker Cover by Jover for Providers’...
CCS ‘on right track’
March 13, 2024Theresa Flaherty, Managing Editor
GLP-1 medications misconception: Nearly 60% of diabetes patients surveyed by CCS mistakenly believe that GLP-1 medications alone are a silver bullet for managing their health. However, these drugs need to be integrated into a long-term holistic care plan.
Education and support gap: The survey results highlight a real need for better education and support for patients managing their diabetes. Diabetes suppliers are well-positioned to...